| Statin-induced myopathies. | |
| | |
MedLine Citation:
|
PMID: 22001973 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Statins are considered to be safe, well tolerated and the most efficient drugs for the treatment of hypercholesterolemia, one of the main risk factor for atherosclerosis, and therefore they are frequently prescribed medications. The most severe adverse effect of statins is myotoxicity, in the form of myopathy, myalgia, myositis or rhabdomyolysis. Clinical trials commonly define statin toxicity as myalgia or muscle weakness with creatine kinase (CK) levels greater than 10 times the normal upper limit. Rhabdomyolysis is the most severe adverse effect of statins, which may result in acute renal failure, disseminated intravascular coagulation and death. The exact pathophysiology of statin-induced myopathy is not fully known. Multiple pathophysiological mechanisms may contribute to statin myotoxicity. This review focuses on a number of them. The prevention of statin-related myopathy involves using the lowest statin dose required to achieve therapeutic goals and avoiding polytherapy with drugs known to increase systemic exposure and myopathy risk. Currently, the only effective treatment of statin-induced myopathy is the discontinuation of statin use in patients affected by muscle aches, pains and elevated CK levels. |
| | |
Authors:
|
Michał Tomaszewski; Karolina M Stępień; Joanna Tomaszewska; Stanisław J Czuczwar |
Related Documents
:
|
9758013 - Drug identity change processes, race, and gender. i. explanations of drug misuse and a ... 21612153 - Stavudine entrapped lipid nanoparticles for targeting lymphatic hiv reservoirs. 7474363 - Nicorandil suppresses a hump on the monophasic action potential and torsade de pointes ... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Pharmacological reports : PR Volume: 63 ISSN: 1734-1140 ISO Abbreviation: Pharmacol Rep Publication Date: 2011 Jul |
Date Detail:
|
Created Date: 2011-10-17 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101234999 Medline TA: Pharmacol Rep Country: Poland |
Other Details:
|
Languages: eng Pagination: 859-66 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, Medical University of Lublin, Jaczewskiego 8, PL 20-954 Lublin, Poland. mdtomaszewski@yahoo.com. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Lipoic acid - biological activity and therapeutic potential.
Next Document: Novel mechanistic and clinical implications concerning the safety of statin discontinuation.